Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclodextrin clathrate of minodronic acid, and preparation method of oral solid preparation of clathrate

A technology of cyclodextrin inclusion compound and minodronic acid, which is applied in the field of pharmacy, can solve the problems of difficult in vitro dissolution and poor water solubility of minodronic acid, etc., and achieve strong magnesium salt, promote drug dissolution, and strong emulsification Effect

Inactive Publication Date: 2017-04-05
TIANJIN HANKANG PHARMA BIOTECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] After reviewing the literature, there are only oral dosage forms on the market, and minodronic acid has poor water solubility, so it is difficult to dissolve it in vitro by conventional techniques

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Preparation of Cyclodextrin Inclusion Compound of Minodronic Acid in Example 1

[0048] Take 200g of sulfobutyl-β-cyclodextrin, add an appropriate amount of purified water and stir to dissolve, add 50g of minodronic acid and stir evenly, pulverize and grind with a colloid mill, let it stand for 12 hours, and dry under reduced pressure to obtain an oral solid preparation. clathrate.

Embodiment 2

[0049] Embodiment 2 tablet preparation

[0050] Minodronic acid cyclodextrin inclusion compound calculated as minodronic acid 50g

[0051] Lactose 38g

[0052] Microcrystalline Cellulose 42g

[0053] Starch 80g

[0054] 2% hydroxypropyl cellulose 10g

[0055] Magnesium Stearate 2g

[0056] Sodium Lauryl Sulfate 5g

[0057] Made into 1000 pieces Preparation method:

[0058] After the cyclodextrin inclusion complex of prescription amount minodronic acid is pulverized through a 120 mesh sieve, it is mixed with lactose, microcrystalline cellulose, starch and sodium lauryl sulfate passing through an 80 mesh sieve to obtain a mixed powder, and 2 The soft material made of hypromellose is granulated through a 24-mesh sieve, ventilated and dried at 55° C., granulated with a 20-mesh sieve, mixed evenly with magnesium stearate and talcum powder, and compressed to obtain tablet cores. Add hydroxypropyl methylcellulose per 1000 tablets 10g in the composition when preparing sustained...

Embodiment 3

[0061] Change the cyclodextrin inclusion complex of minodronic acid in the prescription composition of Example 2 to non-inclusion complex, and prepare tablets according to the method of Example 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the pharmaceutical field, and relates to a cyclodextrin clathrate of minodronic acid, and a preparation method thereof. The clathrate is used to prepare an oral solid preparation. The clathrate comprises minodronic acid and cyclodextrin, the cyclodextrin is sulfobutyl-beta-cyclodextrin, and a mass ratio of the minodronic acid to the cyclodextrin is 1:(2-5).

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to a method for preparing a cyclodextrin inclusion compound of minodronic acid. Background technique [0002] Osteoporosis (OP) is a systemic skeletal disease characterized by low bone mass and degeneration of bone tissue microarchitecture, which can easily lead to reduced bone strength and fractures. Osteoporosis has become the most common senile disease. In addition, hyperthyroidism, rheumatoid arthritis, malabsorption syndrome, multiple myeloma, and excessive use of glucocorticoids, GnRH promoters and antagonists, etc. patients are prone to osteoporosis. Therefore, it is of great significance and broad application prospect to actively develop safe, effective, low side effect and relatively cheap drugs for treating osteoporosis. [0003] Minodronic acid is the third-generation nitrogen-containing aromatic heterocyclic bisphosphonate compound, which was developed by Japan Astella Pharmaceuti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/61A61K47/26A61K47/36A61K47/12A61K47/02A61K47/38A61K47/32A61K47/20A61K9/20A61K31/675A61P19/10A61P3/14
Inventor 严洁
Owner TIANJIN HANKANG PHARMA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com